Advanced heart failure: Where do we stand?

Tousoulis, Dimitris

doi:10.1016/j.hjc.2019.02.007

Cited by 9 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, nearly 10% of HF patients will progress to ADHF. These patients experience poor quality of life, recurrent hospitalizations, and 25-50% mortality within 1 year [3][4][5]. The Heart Failure Association of the ESC has updated the criteria for the definition of ADHF [6] (Table 1 [6], with permission.…”

Section: Advanced Heart Failure (Adhf)mentioning

confidence: 99%

Advanced Heart Failure: Therapeutic Options and Challenges in the Evolving Field of Left Ventricular Assist Devices

Antonopoulos,

Bonios,

Dimopoulos

et al. 2024

JCDD

View full text Add to dashboard Cite

Heart Failure is a chronic and progressively deteriorating syndrome that has reached epidemic proportions worldwide. Improved outcomes have been achieved with novel drugs and devices. However, the number of patients refractory to conventional medical therapy is growing. These advanced heart failure patients suffer from severe symptoms and frequent hospitalizations and have a dismal prognosis, with a significant socioeconomic burden in health care systems. Patients in this group may be eligible for advanced heart failure therapies, including heart transplantation and chronic mechanical circulatory support with left ventricular assist devices (LVADs). Heart transplantation remains the treatment of choice for eligible candidates, but the number of transplants worldwide has reached a plateau and is limited by the shortage of donor organs and prolonged wait times. Therefore, LVADs have emerged as an effective and durable form of therapy, and they are currently being used as a bridge to heart transplant, destination lifetime therapy, and cardiac recovery in selected patients. Although this field is evolving rapidly, LVADs are not free of complications, making appropriate patient selection and management by experienced centers imperative for successful therapy. Here, we review current LVAD technology, indications for durable MCS therapy, and strategies for timely referral to advanced heart failure centers before irreversible end-organ abnormalities.

show abstract